multiple dose bio­equi­va­lence study [Design Issues]

posted by wienui  – Germany/Oman, 2020-08-10 10:00 (1441 d 02:05 ago) – Posting: # 21847
Views: 2,349

Hi Loky do & Helmut,

❝ If we have solifenacin 6 mg (immediate-release) / tamsulosin 0.4 mg modified-release product combination, is multiple-dose bioequivalence study required to be submitted to the European authorities in addition to fast & fed studies, as there is no specific guidance for this product & in GCC region fast & fed studies only accepted.


Yes, you need an MD (SS) study as Helmut mentioned above. Please note that the GCC GL was adopted originally from the EMA GL, therefore it follows it, although some points could be not clear included.

Cheers,
Osama

Complete thread:

UA Flag
Activity
 Admin contact
23,112 posts in 4,858 threads, 1,644 registered users;
60 visitors (0 registered, 60 guests [including 10 identified bots]).
Forum time: 12:05 CEST (Europe/Vienna)

It’s always fun to have your models validated,
but is way more fun to have them trashed.
Finding out you are completely wrong
is a great part of science.    G. Randall Gladstone

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5